New Biotic — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

New Biotic is a private, clinical-stage biotech founded in 1962, leveraging microbiome-derived therapeutics to address ALS, a disease with significant unmet need. Its flagship candidate, RaphaLX™, has received Orphan Drug Designation from both the FDA and EMA and has shown promise in early human studies to slow progression and potentially reverse symptoms. The company collaborates with the Avera Institute for Human Genetics and is developing diagnostic biomarkers while exploring a novel hypothesis linking muscle atrophy to ALS onset.

Amyotrophic Lateral Sclerosis (ALS)Neurodegenerative Diseases

Technology Platform

Microbiome-derived biotherapeutics targeting the gut-brain axis, with a focus on modulating glutamate excitotoxicity. Platform includes development of companion blood-based diagnostic biomarkers for excitotoxicity.

Opportunities

The significant unmet medical need in ALS, with only modestly effective approved therapies, creates a substantial market for a disease-modifying treatment like RaphaLX™.

Orphan drug designations provide regulatory and commercial incentives.

The gut-brain axis platform could be expanded to other neurological and psychiatric disorders, offering long-term pipeline potential.

Risk Factors

High risk of clinical failure as early promising data must be confirmed in rigorous, controlled trials.

The novel scientific hypotheses around muscle atrophy and microbiome intervention are unproven and face skepticism.

The company is pre-revenue and will require substantial capital to fund expensive late-stage ALS trials.

Competitive Landscape

The ALS competitive landscape includes approved drugs (riluzole, edaravone, AMX0035) offering limited benefit, creating a high bar for meaningful improvement. Numerous biopharma companies are actively developing ALS therapies targeting diverse mechanisms (e.g., antisense oligonucleotides, neuroinflammation). New Biotic's microbiome approach is relatively unique but faces competition from both established and emerging players.

More companies in Microbiome Therapeutics →More companies in United States →